Previous studies have documented that, in malignant B-cells, Rituximab elicits a complex and not yet totally understood signalling network contributing to its anti-tumour effect. In this context, we investigated the role of protein kinase C zeta, an atypical PKC isoform, in the cellular response to Rituximab. We found that follicular lymphoma cells displayed an increase in PKC zeta expression and activity levels, compared to non malignant B cells, and that this enzyme was a critical regulator of the classical MAPK module by stimulating Raf-1 kinase activity. PKC zeta appeared to be a significant contributor of abnormal mTOR regulation in follicular lymphoma cells through a MAPK-dependent mechanism. Rituximab was found to inhibit the PKC zeta/MAPK/mTOR module in these cells but not in other B-cell lymphomas.
enzyme was a critical regulator of the classical MAPK module by stimulating Raf-1 kinase activity. PKC zeta appeared to be a significant contributor of abnormal mTOR regulation in follicular lymphoma cells through a MAPK-dependent mechanism. Rituximab was found to inhibit the PKC zeta/MAPK/mTOR module in these cells but not in other B-cell lymphomas.
Importantly, the expression of a constitutively active form of PKC zeta resulted in an efficient protection of these cells towards Rituximab. Altogether, our study describes a new regulatory component of mTOR pathway in follicular cell lymphoma, and demonstrates that PKC zeta is a target for Rituximab. Therefore, PKC zeta could represent an important parameter for Rituximab efficacy and a promising target for future targeted therapy in follicular lymphoma.
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INTRODUCTION
Rituximab (RTX) is an anti-CD20 mouse/human chimeric IgG1-κ antibody that targets the CD20 antigen found on the surface of malignant and normal B cells. RTX used as a single agent has demonstrated efficacy in patients with various lymphoid malignancies, including indolent and aggressive forms of non-Hodgkin's lymphoma (NHL), as well as in chronic lymphocytic leukemia (CLL). Moreover, it has some therapeutic activity in antibody-based autoimmune diseases. 1 However, the most significant contribution of this new agent is that it greatly improves the efficacy of chemotherapy in the treatment of various forms of lymphoid neoplasias, including follicular (FL), mantle cell (MCL) or diffuse large B cell lymphomas (DLBCL).
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The mechanism by which RTX facilitates tumour eradication by chemotherapy remains unknown. Several hypotheses have been raised, including a simple additive effect or a true synergistic mechanism mediated by RTX-induced activation of pro-apoptotic signals. Indeed, as documented by Bonavida and co-workers, RTX-mediated CD20 engagement resulted in reduced expression of Bcl-2 or Bcl-xL, enhanced expression of Fas death receptor, as well as in the negative regulation NF-κB or MAPK signalling pathways, depending on the cellular models. 5, 6 In parallel, our group has described that RTX can also activate the sphingomyelin cycle, a well-defined metabolic process resulting in the accumulation of ceramide, a lipid second messenger which primes cell to inhibition of proliferation and/or apoptosis. 7 Based on these findings, we raised the possibility that, in the context of RTX-treated FL cells, ceramide targets a common regulator of one or several of these pro-survival signalling pathways. This question presents an evident practical interest since, if this is the case, 
MATERIALS AND METHODS

Cell lines and reagents
RL and Karpas-422 are FL cells carrying the t(14;18). There were obtained from the ATCC (American Type Cell Collection) (Rockville, MD, USA) and DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH) respectively. MEC-2 and JVM-3 are B-CLL cell lines obtained from DSMZ. Granta 519 and Rec-1 are MCL cells carrying t (11;14) , and were a gift of Dr. Pelletier and Dr. Hermine (Necker, Paris, France). These cell lines except Granta 519 and MEC-2 were cultured at 37°C in 5% CO 2 in RPMI supplemented with 10% fetal calf serum (FCS), glutamine (2 mM), streptomycin (10 µg/mL) and penicillin (200 U/mL) (Invitrogen, Cergy Pontoise, France). DEAU and LIB derived from DLBCL were kindly provided by Pr. Delsol (INSERM U563, Toulouse, France). These cell lines as well as Granta 519 and MEC-2 were cultured at 37°C in 5% CO 2 in IMDM supplemented with 20% FCS, glutamine (2 mM), streptomycin (10 µg/mL) and penicillin (200 U/mL). Cells were treated at exponentional phase. Fresh CLL were collected from peripheral blood of B-CLL patients after informed consent (service d'hématologie, CHU Purpan, Toulouse, France) and separated by Ficoll-Hypaque density gradient (GE healthcare, Orsay, France 
Isolation of normal B lymphocytes
After isolation of peripheral blood mononuclear cells from healthy donors by Ficoll-Hypaque density-gradient centrifugation, negative selection of B lymphocytes was performed with the B cell isolation kit II human according to the manufacturer's instructions (Miltenyi Biotec, Paris, France). The purity of the enriched B cells (around 90%) was evaluated by flow cytometry using a CD19-PE antibody (BD Biosciences, le Pont de Claix, France). 
Western-blot analysis
Immunokinase assays
Cells were lysed in buffer containing 20 mM HEPES pH 7.4, 12 mM EDTA, 250 mM NaCl, 1% NP-40, 2 µg/mL leupeptin, 2 µg/mL aprotinin, 1 mM PMSF, 0.5 µg/mL benzamidine, and 1 mM DTT. 500 µg of proteins were immunoprecipitated with 3 µg anti-PKCζ, anti-Raf-1 (C-12) or anti-ERK1 (C16) antibodies (Tebu, Le Perray en Yvelines, France) overnight at 4°C. For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
RESULTS
1-PKCζ is constitutively activated in follicular lymphoma cells
PKCζ activity was measured by Western-blot analysis using an antibody directed against the phosphorylated form of PKCζ (Thr 410/403), based on previous studies, including ours, which established the reliability of this method compared to immunokinase assay. [15] [16] [17] As shown in Fig 
2-Rituximab inhibited PKCζ activity
As shown in Fig. 2 , in FL cells, treatment with RTX for 24 hrs resulted in a reduction of PKCζ activity in a dose-dependent manner as attested not only by Western-blot using phospho-PKCζ antibody ( Fig. 2A left panel) but also by immunokinase assay (Fig. 2B) . The latter revealed that, at the maximum concentration of RTX (50 µg/mL), PKCζ inhibition was as potent as 40% reduction. Importantly, following treatment with RTX, PKCζ expression This concentration is relevant with the clinical use of RTX in humans. To test the specificity of RTX, we treated FL cells with human IgG. In these conditions, we found no inhibition of phospho-PKCζ or PKCζ expression even at 50 µg/mL ( Fig. 2A right panel) . Interestingly, RTX had no impact on PKCζ activity in other malignant B cells. Indeed, in repeated experiments (n = 5), we were unable to detect any reduction in PKCζ activity in MCL and DLBCL treated with RTX although used at higher concentrations (data not shown). These results suggest that Rituximab inhibits PKCζ activity, and that this effect is restricted to FL cells.
3-PKCζ inhibition mediates the antagonistic effect of Rituximab on MAPK pathway
Previous studies have documented that PKCζ may regulate ERK by operating at different step of the classical MAPK module, i.e, upstream Raf-1 through RKIP, 18 Raf-1 19 or even MEK. 10 The mechanism by which PKCζ interferes with MAPK pathway appears to be highly dependent of the cellular model but the final inhibitory effect on ERK phosphorylation has been so far documented in mouse fibroblasts, 20 Cos-7, 21 and normal murine B cells. 22 Therefore, we first evaluated the role of PKCζ as a significant regulator of ERK phosphorylation in FL cells. As a matter of fact, the stable transfection of DN-PKCζ in Karpas-422 cells (clone 6E5), which resulted in a decrease of PKCζ activity (Fig. 3A) ,
induced an inhibition of Raf-1 activity (Fig. 3B right panel) as well as MEK and ERK phosphorylation ( Fig. 3B left panel) , compared to the empty vector (clone 2E10). Bonavida and co-workers have described that in the Ramos Burkitt lymphoma cells, treatment with RTX resulted in a significant reduction in the phosphorylation level of MAPK components,
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. As shown in Fig. 3C , this effect was also observed in FL cells. Therefore, it was tempting to speculate that, in RTX-treated cells, ERK inhibition was due to reduced PKCζ activity. To address this question, we evaluated the influence of constitutively active mutant form of PKCζ (CA-PKCζ) in RL cells (clones 6F9 and 7E5) on RTX-mediated ERK inhibition. As expected, expression of CA-PKCζ resulted in increased PKCζ activity (Fig. 3D) . Moreover, as shown in Fig. 3E , in these cells, RTX was no more able to repress ERK activity as revealed by immunokinase assay. These results suggest that PKCζ inhibition governs the inhibitory effect of Rituximab on the MAPK pathway.
4-PKCζ is a regulator of mTOR in FL cells
In a recent study, we described that mTOR pathway is constitutively activated in FL cells such as Karpas-422 and RL, as well as in FL lymph node biopsy specimens. 14 We also
showed that FL cells were sensitive to rapamycin at the same extent than MCL. 24 In the same study, we propose that, in these cells, at least four distinct signalling components, including PI3K/Akt, PLD/phosphatidic acid (PA), Syk, and MAPK, exert a redundant stimulating function converging towards mTOR and its main target, the p70 S6 kinase (p70S6K). Since PKCζ appeared to regulate MAPK (see above), we speculated that PKCζ could also regulate mTOR through a MAPK-dependent mechanism. Indeed, treatment with PKCζ pseudosubstrate inhibitory peptide (PS-PKCζ) resulted in a decrease in p70S6K phosphorylation level, the magnitude of this effect being more pronounced in Karpas-422 than in RL cells (Fig. 4A) . At the concentrations used (40 and 60 µM), we have previously found that PS-PKCζ induced a dramatic and specific reduction in basal PKCζ activity as demonstrated with purified PKCζ in a cell-free system. 25 Importantly, p70S6K
phosphorylation level has been evaluated by using an antibody directed against the phosphorylated site specifically targeted by mTOR (Thr 389). In order to strengthen the role In DN-PKCζ cells (clones 5E9 and 6E5), we found that p70S6K phosphorylation level was much lower, compared to cells transfected with the empty vector (clone 2E10) (Fig. 4B) .
These results suggest that PKCζ is indeed a regulator of mTOR in FL cells.
5-PKCζ inhibition mediates the antagonistic effect of Rituximab on mTOR pathway
Therefore, since RTX acts as a PKCζ inhibitor, we hypothesized that RTX could also interfere with mTOR pathway. Indeed, treatment with RTX for 24 hrs resulted in a dosedependent decrease of mTOR activity in both Karpas-422 and RL cells (Fig. 5A) . Moreover, the expression of CA-PKCζ in RL (Fig. 5B ) or in Karpas-422 cells (data not shown) prevented RTX-induced decrease of p70S6K phosphorylation. These results showed that RTX inhibited mTOR pathway in FL cells, and that this effect was efficiently regulated by PKCζ.
Based on these findings, we investigated whether RTX could negatively regulate mTOR pathway in other human B cell lymphomas. We found that RTX had no effect on p70S6K phosphorylation level in MCL (Granta and Rec-1) or in DLBCL (DEAU and LIB) (data not shown). This result was expected since, as described above, in these cells, RTX was unable to inhibit PKCζ. Based on our previous study, we also investigated whether RTX could interfere with the other components of mTOR regulation in FL cells. However, we found that treatment with RTX induced no significant decrease in the activities of PLD, Syk and PI3K (data not shown). Altogether, these results suggest that, in FL cells, Rituximab inhibits mTOR pathway through PKCζ inhibition.
-Influence of PKCζ on FL cell response to Rituximab
In our previous work, we have shown that mTOR plays an important role in FL cells proliferation. 14 The present study established that RTX inhibited mTOR and that this effect Moreover, since both RTX (this study) and rapamycin ( 14 ) target mTOR, we raised the possibility that combined therapy with the two drugs could result in an additive effect. This is indeed the case as illustrated in Fig. 6B based on cell viability measurement after 7 days incubation. Altogether, these findings support the idea that PKCζ exerts a survival function in B cells and that its expression is abnormally regulated in B cell neoplasms through yet undefined mechanisms. The reason for which PKCζ is not only overexpressed but also activated remains also unknown. In other cellular models, it has been shown that this enzyme can be activated by lipid second messengers such as PA, Src kinases, oncogenic products, or growth factors. 9 Thus, it is possible that FL cells possess intrinsically abnormal regulation of one or several of these pathways resulting to amplification of PKCζ function. Since we have previously described that PLD activity was remarkably high in FL cells, 14 a plausible candidate for PKCζ activity regulation is PA. Moreover, based our previous study which shows that Syk, a nonreceptor tyrosine kinase, is overexpressed in FL cells and plays an important role in FL survival, we also investigated whether Syk could regulate PKCζ in these cells. However, we found that pharmacological inhibition of Syk by piceatannol or Syk depletion by siRNA had no influence on PKCζ expression or activity (data not shown).
Our study shows for the first time that RTX inhibits PKCζ in FL cells, but not in DLBCL and MCL cells. In a previous study, we described that RTX-mediated CD20 activation resulted in the induction of SM cycle and subsequent accumulation of ceramide, a plausible candidate for PKCζ inhibition. Indeed, previous studies have established that ceramide specifically binds to isolated PKCζ and regulates its kinase activity in vitro. Although low doses of ceramide may exert a stimulatory effect, ceramide is a potent inhibitor of the enzyme when used at high doses. 8 In intact cells, recent studies have indicated that ceramide could also act indirectly by facilitating the binding of the enzyme to its inhibitor protein, Par-4.
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The effect of ceramide on PKCζ could be even more complex since it can also alter its intracellular redistribution. 29 Based on these findings, we propose a model in which, in FL cells, ceramide accumulated during RTX-induced SM cycle activation is responsible for PKCζ inhibition. The fact that, in FL cells, we found that exogenous ceramide could inhibit PKCζ (data not shown), thus mimicking RTX effect, argued for this hypothesis. However, it remains to understand why treatment with RTX has no effect on PKCζ in DLBCL or MCL.
This result raised several possibilities including abnormal regulation SM cycle, enhanced ceramide metabolism or reduced Par-4 expression. At the present time, we found no difference in term of ceramide production or Par-4 expression between the different cell lines (data no shown).
Our study shows for the first time that PKCζ is an important component for regulating mTOR in FL cells. In a recent study, we have reported that, in FL cells, mTOR is constitutively
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From activated, and that mTOR is regulated by at least three distinct pathways: a PI3K-Akt module, PLD/PA, and a Syk, PI3K-and PLD-independent, autonomous pathway. 14 In the present study, we describe another pathway consisting in a PKCζ-Raf-MEK-ERK module. The functional link between PKCζ and the classical MAPK module was not unexpected since we and others have established in other conditions that PKCζ may indeed interact with and regulates Raf-1. 19 Moreover, the role of ERK as a regulator of mTOR pathway has been also established. 30 The identification of another mTOR regulating component illustrates the complexity of mTOR network in FL cells. The fact that mTOR appears to be regulated by several distinct intracellular signalling pathways, designates this kinase as an important molecular target for FL therapy. It is important to note that the inhibitory effect of RTX on mTOR is selectively related to the inhibition of the PKCζ-MAPK module. Indeed, we found that, at least in FL cells, RTX had no effect on Syk activity and inhibited neither PLD activity nor PI3K-Akt pathway (data not shown). The latter result conflicts with recent findings coming from Bonavida's group, which described that RTX inhibits Akt phosphorylation at both Ser 473 and Thr 308 sites in Ramos and Daudi cells. 31 These discrepancies illustrate the cell specificity of RTX molecular effects.
Our results suggest that RTX inhibits the Raf/MEK/ERK signaling pathway by inhibiting PKCζ. The inhibitory effect of RTX on MAPK has been largely documented by Bonavida and co-workers. 23 This group has shown that RTX acts by increasing the expression of RKIP, a negative regulator of Raf-1, and that the subsequent adverse regulation of MAPK resulted in Bcl-xL downregulation. As far as FL cells are concerned, we were unable to detect any variation of RKIP, even after prolonged RTX exposure, as well as modification of Bcl-2 family protein expression (data not shown). Again, these discrepancies confirm that RTX operates differently depending on lymphoma cell subtype.
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Our study may have potentially important clinical implications. First, we show that combined therapy with RTX and rapamycin resulted in an additive anti-leukemic effect. This result should encourage investigators to design in FL clinical studies based on the association between RTX and new derivatives directed against mTOR such as RAD001. Moreover, the impact of RTX on PKCζ could also explain the synergistic effect between RTX and chemotherapy. Indeed, we and others have previously documented that this enzyme plays an important role not only in the regulation of post-DNA damage response, 12, 17, 26 but also in drug-induced DNA damage or DNA repair. Thus, we have previously described that PKCζ inhibits the formation of DNA double strand break generated by topoisomerase II poisons through topoisomerase II activity inhibition, resulting in a significant protection against anthracyclines or podophyllotoxins. 17 In another study, we have also reported that PKCζ is efficient for regulating nucleotide excision repair, an important contributor for protecting cells against cisplatin derivatives. 33 Finally, we have also reported that PKCζ is a potent regulator of radical oxygen species (ROS) detoxication. 32 Since ROS are important mediators of anthracyclin-induced cytotoxicity, it is also conceivable that RTX-induced PKCζ inhibition contributes to sensitize cells to doxorubicin contained in R-CHOP regimen by reducing antioxidant defenses.
To conclude, our study shows that, in FL cells, RTX inhibits a PKCζ-MAPK-mTOR module, and that PKCζ is not only a target for this antibody but also a potent regulator of its intrinsic anti-leukemic effect. 
